Sugi Predict

Sugi Predict / Compounds / SCHEMBL534435

SCHEMBL534435

SCHEMBL534435

CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCOc1ccc(C(N)c2ccc(OCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.60
▸ NR5A1 Q13285 1/20 0.54
▸ LMNA P02545 3/20 0.52
▸ MMP9 P14780 1/20 0.52
▸ MMP8 P22894 1/20 0.52
▸ MMP13 P45452 1/20 0.52
▸ TP53 P04637 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ LTA4H P09960 3/20 0.49
▸ PLA2G4B P0C869 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL533718 0.95 SLC2A1 (0.66) SLC2A1NR5A1LMNAMMP9MMP8
SCHEMBL30469502 0.95 SLC2A1 (0.66) SLC2A1NR5A1LMNAMMP9MMP8
SCHEMBL12496080 0.87 LTA4H (0.62) SLC2A1NR5A1LMNAMMP9MMP8
SCHEMBL23865150 0.84 SLC2A1 (0.66) SLC2A1NR5A1LMNAMMP9MMP8
SCHEMBL534432 0.83 NR5A1 (0.54) SLC2A1NR5A1LMNAMMP9MMP8
SCHEMBL8501698 0.83 SLC2A1 (0.64) SLC2A1NR5A1LMNAMMP9MMP8
SCHEMBL8505207 0.83 SLC2A1 (0.64) SLC2A1NR5A1LMNAMMP9MMP8
SCHEMBL8503473 0.83 SLC2A1 (0.64) SLC2A1NR5A1LMNAMMP9MMP8
SCHEMBL8501526 0.83 SLC2A1 (0.64) SLC2A1NR5A1LMNAMMP9MMP8
Hydrochloric Acid SCHEMBL11741891 0.81 SLC2A1 (0.67) SLC2A1NR5A1LMNAMMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2711370-B1 METHOD FOR PRODUCING OLIGONUCLEOTIDES AJINOMOTO KK (JP) 2018-01-03 — — EP claimed
US-9790497-B2 Morpholino oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2017-10-17 — — US claimed
EP-3015467-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD Ajinomoto Co., Inc. (JP) 2016-05-04 — — EP claimed
US-20160076033-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD AJINOMOTO CO., INC. (JP) 2016-03-17 — — US claimed
US-9169187-B2 Method of making peptides using diphenylmethane compound AJINOMOTO CO., INC. (JP) 2015-10-27 — — US claimed
US-9029528-B2 Solution-based method of making oligonucleotides via phosphoramidite coupling AJINOMOTO CO., INC. (JP) 2015-05-12 — — US claimed
US-20140213761-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC (JP) 2014-07-31 — — US claimed
US-8722934-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2014-05-13 — — US claimed
EP-2711370-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE Ajinomoto Co., Inc. (JP) 2014-03-26 — — EP claimed
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2012-11-22 — — US claimed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 — — EP claimed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US claimed
US-12351601-B2 Method for producing peptide continuously AJINOMOTO CO., INC. (JP) 2025-07-08 — — US disclosed
WO-2025122535-A2 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — WO disclosed
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — US disclosed
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD AJINOMOTO CO., INC. (JP) 2024-01-18 — — US disclosed
EP-2711370-A1 METHOD FOR PRODUCING OLIGONUCLEOTIDE Ajinomoto Co., Inc. (JP) 2014-03-26 — — EP disclosed
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE AJINOMOTO CO., INC. (JP) 2012-11-22 — — US disclosed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 — — EP disclosed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249374-A1 DIPHENYLMETHANE COMPOUND CCKAR, DNPEP, QPCTL SLC2A1 4330/4885NR5A1 2883/4885LMNA 300/4885
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS VIP, RNGTT, SSU72 SLC2A1 4401/4885NR5A1 1636/4885LMNA 1169/4885
US-20140213761-A1 DIPHENYLMETHANE COMPOUND CCKAR, VIP, CCKBR SLC2A1 3858/4885NR5A1 3226/4885LMNA 310/4885
US-12351601-B2 Method for producing peptide continuously VIP, NPPA, NGLY1 SLC2A1 4042/4885NR5A1 2347/4885LMNA 584/4885
US-20120296074-A1 PRODUCTION METHOD OF OLIGONUCLEOTIDE RNGTT, POLM, RNMT SLC2A1 3642/4885NR5A1 2010/4885LMNA 1883/4885
US-20240018180-A1 OLIGONUCLEOTIDE PRODUCTION METHOD RNGTT, NOX4, POLRMT SLC2A1 3145/4885NR5A1 1180/4885LMNA 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.